WHAT IS CLAIMED IS:

1. A method for treating aberrant immune responses in a sample of ex vivo peripheral blood mononuclear cells (PBMCs) comprising adding a regulatory composition to said population.

2. A method for treating an autoimmune disorder in a patient comprising:

a) removing peripheral blood mononuclear cells (PBMC) from said patient;

b) treating said cells with a regulatory composition for a time sufficient to suppress aberrant immune responses; and

c) reintroducing said cells to said patient.

3. A method according to claim 1 or 2 wherein said immune response is an antibody-mediated immune response.

4. A method according to claim 1 or 2 wherein said immune response is a cell-mediated immune response.

5. A method according to claim 3 wherein said immune response is a cell mediated immune response.

6. A method according to claim 4 wherein said immune response is cytotoxicity.

7. A method according to claim 1 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises TGF-β.

8. A method according to claim 7 wherein said treatment comprises the prevention of T cells from becoming cytotoxic.

9. A method according to claim 7 wherein said treatment comprises a decrease in IL-10 production.

10. A method according to claim 7 wherein said treatment comprises the production of increased levels of TNF-α.

11. A method according to claim 7 wherein said treatment comprises the production of increased levels of TNF-α, IL-2 and IFN-γ.

12. A method according to claim 1 or 2 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises TGF-β.

13. A method according to claim 12 wherein said treatment comprises the prevention of T cells from becoming cytotoxic.

14. A method according to claim 12 wherein said treatment comprises a decrease in IL-10 production.

15. A method according to claim 12 wherein said treatment comprises the production of increased levels of TNF-α.

16. A method according to claim 12 wherein said treatment comprises the production of increased levels of TNF-α, IL-2 and IFN-γ.

17. A method according to claim 12 wherein said treatment comprises treating naive CD4+ T cells with a stimulant such that said CD4+ cells produce immunosuppressive levels of active TGF-β

18. A method according to claim 12 wherein said treatment comprises stimulating naive CD4+ T cells in the presence of TGF-β to expand said CD4+ cell population.

19. A method according to claim 12 wherein said regulatory composition comprises CD2 activators.

20. A method according to claim 12 wherein said regulatory composition comprises TGF-β.

21. A kit for the treatment of an autoimmune disorder comprising:

a) a cell treatment container adapted to receive cells from a patient with an autoimmune disorder; and

b) at least one dose of an regulatory composition.

22. A kit according to claim 21 wherein said autoimmune disorder is an antibody-mediated disease.

23. A kit according to claim 21 wherein said autoimmune disorder is an cell-mediated disease.